8-K Announcements
6Material company update
Mar 4, 2026·SEC
Material company update
Jan 30, 2026·SEC
Material company update
Nov 4, 2025·SEC
OmniAb, Inc.(OABI)Earnings, Financials & Key Ratios
OABI•NASDAQ
$1.43
$206M mkt cap·Price updated May 6, 2026
AboutOmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.Show more
- Revenue$19M-29.3%
- EBITDA-$50M+2.3%
- Net Income-$65M-4.4%
- EPS (Diluted)-0.57+6.6%
- Gross Margin98.38%-1.6%
- EBITDA Margin-266.6%-38.2%
- Operating Margin-383.15%-35.7%
- Net Margin-347.04%-47.6%
- ROE-23.36%-13.4%
- ROIC-19.68%-6.9%
- Debt/Equity0.08-5.4%
OABI Key Insights
OmniAb, Inc. (OABI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Shares diluted 11.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OABI Price & Volume
OmniAb, Inc. (OABI) stock price & volume — 10-year historical chart
Loading chart...
OABI Growth Metrics
OmniAb, Inc. (OABI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-4.31%
3 Years-31.89%
TTM-29.27%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM5%
Return on Capital
10 Years-14.31%
5 Years-17.11%
3 Years-21.7%
Last Year-24.03%
OABI Recent Earnings
OmniAb, Inc. (OABI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Mar 4, 2026EPS
$0.11
Est $0.08
-37.5%
Revenue
$8M
Est $9M
-7.0%
Q4 2025
Nov 4, 2025EPS
$0.14
Est $0.14
-2.9%
Revenue
$2M
Est $6M
-60.3%
Q3 2025
Aug 6, 2025EPS
$0.15
Est $0.14
-7.1%
Revenue
$4M
Est $6M
-31.0%
Q2 2025
May 8, 2025EPS
$0.17
Est $0.17
+0.0%
Revenue
$4M
Est $4M
-7.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 4, 2026 | $0.11vs $0.08-37.5% | $8Mvs $9M-7.0% |
| Q4 2025 | Nov 4, 2025 | $0.14vs $0.14-2.9% | $2Mvs $6M-60.3% |
| Q3 2025 | Aug 6, 2025 | $0.15vs $0.14-7.1% | $4Mvs $6M-31.0% |
| Q2 2025 | May 8, 2025 | $0.17vs $0.17+0.0% | $4Mvs $4M-7.5% |
Based on last 12 quarters of dataView full earnings history →
OABI Peer Comparison
OmniAb, Inc. (OABI) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ADCT | 490.96M | 3.86 | -3.45 | 14.85% | -173.02% | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ABCL | 1.52B | 5.04 | -10.29 | 160.56% | -194.89% | -15.14% | 0.14 | |
 TWST | 3.71B | 59.53 | -45.79 | 20.32% | -19.85% | -17.46% | 0.29 | |
 SEER | 105.44M | 1.89 | -1.36 | -8.13% | -486.02% | -29.19% | 0.08 |
Compare OABI vs Peers
OmniAb, Inc. (OABI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OABI Income Statement
OmniAb, Inc. (OABI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 18.32M | 23.27M | 34.75M | 59.08M | 34.16M | 26.39M | 18.67M |
| Revenue Growth % | - | 27.02% | 49.34% | 70.02% | -42.17% | -22.75% | -29.27% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 303K |
| COGS % of Revenue | - | - | - | - | - | - | 1.62% |
| Gross Profit | 18.32M▲ 0% | 23.27M▲ 27.0% | 34.75M▲ 49.3% | 59.08M▲ 70.0% | 34.16M▼ 42.2% | 26.39M▼ 22.8% | 18.36M▼ 30.4% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 98.38% |
| Gross Profit Growth % | - | 27.02% | 49.34% | 70.02% | -42.17% | -22.75% | -30.42% |
| Operating Expenses | 31.34M | 48.89M | 70.36M | 85.72M | 103.58M | 100.89M | 87.33M |
| OpEx % of Revenue | 171.12% | 210.12% | 202.48% | 145.11% | 303.19% | 382.3% | 467.87% |
| Selling, General & Admin | 8.65M | 10.22M | 16.95M | 24.9M | 33.31M | 30.74M | 29.21M |
| SG&A % of Revenue | 47.23% | 43.94% | 48.77% | 42.15% | 97.51% | 116.48% | 156.51% |
| Research & Development | 13.21M | 24.8M | 39.23M | 48.36M | 56.52M | 55.11M | 47.75M |
| R&D % of Revenue | 72.1% | 106.57% | 112.9% | 81.87% | 165.45% | 208.82% | 255.83% |
| Other Operating Expenses | 9.49M | 13.87M | 14.18M | 12.46M | 13.74M | 15.04M | 10.36M |
| Operating Income | -13.03M▲ 0% | -25.62M▼ 96.7% | -35.61M▼ 39.0% | -26.65M▲ 25.2% | -69.42M▼ 160.5% | -74.5M▼ 7.3% | -71.52M▲ 4.0% |
| Operating Margin % | -71.12% | -110.12% | -102.48% | -45.11% | -203.19% | -282.3% | -383.15% |
| Operating Income Growth % | - | -96.69% | -38.97% | 25.16% | -160.5% | -7.32% | 4.01% |
| EBITDA | -2.43M | -13M | -19.36M | -8.4M | -49.92M | -50.92M | -49.76M |
| EBITDA Margin % | -13.29% | -55.85% | -55.71% | -14.22% | -146.12% | -192.94% | -266.6% |
| EBITDA Growth % | - | -433.94% | -48.95% | 56.61% | -494.38% | -2% | 2.27% |
| D&A (Non-Cash Add-back) | 10.59M | 12.63M | 16.25M | 18.25M | 19.5M | 23.58M | 21.75M |
| EBIT | -13.85M | -23.55M | -34.34M | -26.65M | -69.42M | -74.5M | -71.52M |
| Net Interest Income | 0 | -5K | -7K | 587K | 5.05M | 3.11M | 2.66M |
| Interest Income | 0 | 0 | 0 | 587K | 5.05M | 3.11M | 2.66M |
| Interest Expense | 0 | 5K | 7K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 1.9M | 1.26M | 587K | 5.06M | 3.09M | 5.22M |
| Pretax Income | -13.03M▲ 0% | -23.73M▼ 82.1% | -34.35M▼ 44.8% | -26.06M▲ 24.1% | -64.36M▼ 147.0% | -71.41M▼ 11.0% | -66.29M▲ 7.2% |
| Pretax Margin % | -71.12% | -101.98% | -98.85% | -44.11% | -188.39% | -270.59% | -355.16% |
| Income Tax | 562K | -6.17M | -7.31M | -3.73M | -13.74M | -9.38M | -1.51M |
| Effective Tax Rate % | -4.31% | 26.01% | 21.28% | 14.3% | 21.35% | 13.13% | 2.29% |
| Net Income | -13.59M▲ 0% | -17.56M▼ 29.2% | -27.04M▼ 54.0% | -22.33M▲ 17.4% | -50.62M▼ 126.6% | -62.03M▼ 22.5% | -64.78M▼ 4.4% |
| Net Margin % | -74.18% | -75.46% | -77.82% | -37.8% | -148.16% | -235.05% | -347.04% |
| Net Income Growth % | - | -29.2% | -54.02% | 17.41% | -126.65% | -22.55% | -4.43% |
| Net Income (Continuing) | -13.59M | -17.56M | -27.04M | -22.33M | -50.62M | -62.03M | -64.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.12▲ 0% | -0.15▼ 25.0% | -0.24▼ 60.0% | -0.26▼ 8.3% | -0.51▼ 96.2% | -0.61▼ 19.6% | -0.57▲ 6.6% |
| EPS Growth % | - | -25% | -60% | -8.33% | -96.15% | -19.61% | 6.56% |
| EPS (Basic) | -0.12 | -0.15 | -0.24 | -0.26 | -0.51 | -0.61 | -0.57 |
| Diluted Shares Outstanding | 114.82M | 114.82M | 114.82M | 85.32M | 99.68M | 102.36M | 113.64M |
| Basic Shares Outstanding | 114.82M | 114.82M | 114.82M | 85.32M | 99.68M | 102.36M | 113.64M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
OABI Balance Sheet
OmniAb, Inc. (OABI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.79M | 16.65M | 22.54M | 124.95M | 94.9M | 68.14M | 65.34M |
| Cash & Short-Term Investments | 0 | 0 | 0 | 88.27M | 86.98M | 59.43M | 54.02M |
| Cash Only | 0 | 0 | 0 | 33.39M | 16.36M | 27.6M | 25.52M |
| Short-Term Investments | 0 | 0 | 0 | 54.88M | 70.63M | 31.84M | 28.5M |
| Accounts Receivable | 7.77M | 15.88M | 21.14M | 30.29M | 3.84M | 5.27M | 7.39M |
| Days Sales Outstanding | 154.9 | 249.03 | 222.02 | 187.14 | 41.07 | 72.91 | 144.51 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 21K | 774K | 1.41M | 6.39M | 4.07M | 3.43M | 3.93M |
| Total Non-Current Assets | 254.53M | 278.73M | 281.92M | 296.26M | 280.32M | 257.42M | 235.57M |
| Property, Plant & Equipment | 4.32M | 5.98M | 20.13M | 41.46M | 38.13M | 33.28M | 24.97M |
| Fixed Asset Turnover | 4.24x | 3.89x | 1.73x | 1.42x | 0.90x | 0.79x | 0.75x |
| Goodwill | 77.11M | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M |
| Intangible Assets | 172.98M | 186.64M | 176.32M | 167.24M | 155.47M | 138.06M | 125.15M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 115K | 2.13M | 1.5M | 3.58M | 2.75M | 2.1M | 1.47M |
| Total Assets | 262.32M▲ 0% | 295.38M▲ 12.6% | 304.46M▲ 3.1% | 421.21M▲ 38.3% | 375.23M▼ 10.9% | 325.56M▼ 13.2% | 300.91M▼ 7.6% |
| Asset Turnover | 0.07x | 0.08x | 0.11x | 0.14x | 0.09x | 0.08x | 0.06x |
| Asset Growth % | - | 12.6% | 3.08% | 38.34% | -10.92% | -13.24% | -7.57% |
| Total Current Liabilities | 6.14M | 14.28M | 20.58M | 26.02M | 23.12M | 15.09M | 16.25M |
| Accounts Payable | 806K | 469K | 2.92M | 2.97M | 4.41M | 2.3M | 1.88M |
| Days Payables Outstanding | - | - | - | - | - | - | 2.26K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 3.88M |
| Deferred Revenue (Current) | 0 | 7.16M | 10.79M | 8.21M | 6.85M | 2.34M | 3.16M |
| Other Current Liabilities | 4.55M | 3.79M | 4.92M | 8.18M | 7.8M | 6.67M | 7.33M |
| Current Ratio | 1.27x | 1.17x | 1.10x | 4.80x | 4.11x | 4.52x | 4.02x |
| Quick Ratio | 1.27x | 1.17x | 1.10x | 4.80x | 4.11x | 4.52x | 4.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 38M | 45.57M | 49.58M | 53.82M | 37.52M | 22.85M | 17.63M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.27M | 2.01M | 13.27M | 24.02M | 22.07M | 19.38M | 16.45M |
| Deferred Tax Liabilities | 0 | 28.93M | 21.96M | 21.34M | 11.35M | 2.31M | 785K |
| Other Non-Current Liabilities | 35.72M | 6.4M | 5.12M | 4.13M | 3.23M | 1.04M | 393K |
| Total Liabilities | 44.13M | 59.84M | 70.16M | 79.84M | 60.64M | 37.94M | 33.89M |
| Total Debt | 2.58M | 2.59M | 13.85M | 25.8M | 25.56M | 23.16M | 20.33M |
| Net Debt | 2.58M | 2.59M | 13.85M | -7.59M | 9.2M | -4.43M | -5.19M |
| Debt / Equity | 0.01x | 0.01x | 0.06x | 0.08x | 0.08x | 0.08x | 0.08x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | -5124.60x | -5087.00x | - | - | - | - |
| Total Equity | 218.19M▲ 0% | 235.54M▲ 8.0% | 234.31M▼ 0.5% | 341.37M▲ 45.7% | 314.58M▼ 7.8% | 287.62M▼ 8.6% | 267.03M▼ 7.2% |
| Equity Growth % | - | 7.95% | -0.52% | 45.69% | -7.85% | -8.57% | -7.16% |
| Book Value per Share | 1.90 | 2.05 | 2.04 | 4.00 | 3.16 | 2.81 | 2.35 |
| Total Shareholders' Equity | 218.19M | 235.54M | 234.31M | 341.37M | 314.58M | 287.62M | 267.03M |
| Common Stock | 218.19M | 0 | 0 | 12K | 12K | 12K | 14K |
| Retained Earnings | 0 | 0 | 0 | 11.25M | -39.37M | -101.4M | -166.18M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 9K | 50K | 27K | 12K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OABI Cash Flow Statement
OmniAb, Inc. (OABI) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.2M | 3.62M | -5.67M | -3.59M | 2.35M | -39.66M | -36.45M |
| Operating CF Margin % | -28.36% | 15.55% | -16.32% | -6.07% | 6.87% | -150.29% | -195.3% |
| Operating CF Growth % | - | 169.66% | -256.73% | 36.76% | 165.43% | -1789.99% | 8.09% |
| Net Income | -13.59M | -17.56M | -27.04M | -22.33M | -50.62M | -62.03M | -64.78M |
| Depreciation & Amortization | 10.92M | 13.14M | 16.25M | 18.25M | 19.5M | 23.58M | 21.75M |
| Stock-Based Compensation | 6.66M | 9.16M | 15.06M | 18.32M | 24.82M | 21.5M | 15.82M |
| Deferred Taxes | 557K | -6.18M | -7.33M | -6.42M | -12.54M | -9.04M | 0 |
| Other Non-Cash Items | -818K | 331K | 9K | -572K | -3.68M | -3.5M | -4.3M |
| Working Capital Changes | -8.92M | 4.73M | -2.63M | -10.83M | 24.87M | -10.17M | -4.95M |
| Change in Receivables | -4.29M | 339K | 6.02M | -12.74M | 26.9M | -625K | 189K |
| Change in Inventory | 0 | 0 | -1.51M | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 1.51M | 15.07M | 920K | -2.41M | -231K |
| Cash from Investing | -12.1M | -26.98M | -4.03M | -73.31M | -18.38M | 37.88M | 6.47M |
| Capital Expenditures | -255K | -1.75M | -4.07M | -17.17M | -1.64M | -1.88M | -565K |
| CapEx % of Revenue | 1.39% | 7.53% | 11.71% | 29.06% | 4.81% | 7.1% | 3.03% |
| Acquisitions | -11.84M | -27.13M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 1.9M | -1.22M | -1.44M | -4.44M | -400K | 3M |
| Cash from Financing | 17.29M | 23.36M | 9.7M | 110.74M | -892K | 13.02M | 27.91M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 0 | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 17.29M | 23.36M | 9.7M | 14.5M | -892K | 1.65M | -450K |
| Net Change in Cash | 0▲ 0% | 0▲ 0% | 0▲ 0% | 33.84M▲ 0% | -16.92M▼ 150.0% | 11.24M▲ 166.4% | -2.07M▼ 118.5% |
| Free Cash Flow | -5.45M▲ 0% | 1.87M▲ 134.2% | -9.74M▼ 622.1% | -20.75M▼ 113.0% | 703K▲ 103.4% | -41.54M▼ 6008.8% | -37.02M▲ 10.9% |
| FCF Margin % | -29.75% | 8.02% | -28.04% | -35.13% | 2.06% | -157.4% | -198.33% |
| FCF Growth % | - | 134.24% | -622.08% | -113.05% | 103.39% | -6008.82% | 10.88% |
| FCF per Share | -0.05 | 0.02 | -0.08 | -0.24 | 0.01 | -0.41 | -0.33 |
| FCF Conversion (FCF/Net Income) | 0.38x | -0.21x | 0.21x | 0.16x | -0.05x | 0.64x | 0.56x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 2.61M | 16K | 0 |
OABI Key Ratios
OmniAb, Inc. (OABI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -6.23% | -7.74% | -11.51% | -7.76% | -15.43% | -20.6% | -23.36% |
| Return on Invested Capital (ROIC) | -4.43% | -8.38% | -10.98% | -6.87% | -15.84% | -18.41% | -19.68% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 98.38% |
| Net Margin | -74.18% | -75.46% | -77.82% | -37.8% | -148.16% | -235.05% | -347.04% |
| Debt / Equity | 0.01x | 0.01x | 0.06x | 0.08x | 0.08x | 0.08x | 0.08x |
| Interest Coverage | - | -5124.60x | -5087.00x | - | - | - | - |
| FCF Conversion | 0.38x | -0.21x | 0.21x | 0.16x | -0.05x | 0.64x | 0.56x |
| Revenue Growth | - | 27.02% | 49.34% | 70.02% | -42.17% | -22.75% | -29.27% |
OABI SEC Filings & Documents
OmniAb, Inc. (OABI) SEC filings — annual & quarterly reports (10-K, 10-Q)
OABI Frequently Asked Questions
OmniAb, Inc. (OABI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
OmniAb, Inc. (OABI) reported $18.7M in revenue for fiscal year 2025. This represents a 2% increase from $18.3M in 2019.
OmniAb, Inc. (OABI) saw revenue decline by 29.3% over the past year.
OmniAb, Inc. (OABI) reported a net loss of $64.8M for fiscal year 2025.
Dividend & Returns
OmniAb, Inc. (OABI) has a return on equity (ROE) of -23.4%. Negative ROE indicates the company is unprofitable.
OmniAb, Inc. (OABI) had negative free cash flow of $37.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More OABI
OmniAb, Inc. (OABI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates